繁體版 / 簡體版
 
R&D PORTFOLIO
/ FB825

FB825

Indication
Atopic Dermatitis (AD), Allergic Asthma, Hyper IgE Syndrome and Food Allergy.
Product Advantages
1.Novel target, inhibiting the origin of IgE production.
2.Fulfill the unmet need of patients with high IgE (IgE > 1500 IU/mL)
3.Clear Pharmacological mechanism, mild side-effects.
4.Combine with Omalizumab or other anti-allergy drug reducing drug dosage and achieving optimal efficacy.
5.Potential of preventive application in allergy.
6.Broad indications, applicable to various IgE related allergic diseases.
7.Expecting to be administrated once every 2~3 months, improving the convenience of patients and reducing the medical cost.
Status
Phase II clinical trial
Mechanism
FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane form IgE, leading to death of IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC)
Potential Market
USD 20.8 billion in allergic disease/allergic asthma in 2024
  • FB825, a new generation of therapeutic monoclonal antibody (humanized; IgG1) for allergic disease, specifically binds to the CεmX domain on membrane-bound IgE B cells and induces targeted cells undergoing apoptosis and ADCC. It kills the IgE+ B lymphocytes directly to prevent IgE-plasma cell differentiation and reduce IgE production. FB825 potentially has both therapeutic and preventive effects in allergic disease.
  • FB825 is under global patent protection. Patents have been granted by majority of advanced countries such as US, EU, Japan and China.
  • Phase I clinical study of FB825 has finished in U.S with confirmed safety results in healthy subjects. Orphan Drug Designation of FB825 was granted by US FDA for treatment of Hyper IgE syndrome (HIES). Phase II studies were approved in HIES and allergic asthma. FB825 was also granted the phase II approval in Atopic Dermatitis (AD) by the Taiwan Food and drug Administration (TFDA).


陕西快乐十分中奖技巧 快乐10分开奖直播草稿 vr赛车游戏怎么玩 比特币官网下载软件 湖北快三走势图表了3d 竞彩足球比分直播新浪网 吉祥棋牌下载安装下载安装 河内5分彩官网 河南11选5开奖号码公告 日本棒球比分直播即时比分 名人彩票官方网站-Welcome 福建快三时间开奖结果 体彩七星彩开奖时间 国债期货软件下载 欢乐斗地主ipadiphone 贵州快三顶测 浙江体彩6+1开奖结果查询果